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Objective: Neuroendocrine abnormalities, such as activation of the hypothalamic-pituitary-adrenal (HPA)
axis, are associated with obesity; however, few large-scale population-based studies have examined HPA
axis and markers of obesity. We examined the cross-sectional association of the cortisol awakening
response (CAR) and diurnal salivary cortisol curve with obesity.
Design and Methods: The Multiethnic Study of Atherosclerosis Stress Study includes 1,002 White,
Hispanic, and Black men and women (mean age 65 6 9.8 years) who collected up to 18 salivary cortisol
samples over 3 days. Cortisol profiles were modeled using regression spline models that incorporated
random parameters for subject-specific effects. Cortisol curve measures included awakening cortisol,
CAR (awakening to 30-min postawakening), early decline (30 min to 2-h postawakening), late decline (2-h
postawakening to bedtime), and the corresponding areas under the curve (AUC). Body mass index (BMI)
and waist circumference (WC) were used to estimate adiposity.
Results: For the entire cohort, both BMI and WC were negatively correlated with awakening cortisol (P <
0.05), AUC during awakening rise, and early decline and positively correlated to the early decline slope
(P < 0.05) after adjustments for age, race/ethnicity, gender, diabetes status, socioeconomic status, b-
blockers, steroids, hormone replacement therapy, and smoking status. No heterogeneities of effects were
observed by gender, age, and race/ethnicity.
Conclusions: Higher BMI and WC are associated with neuroendocrine dysregulation, which is present in
a large population sample, and only partially explained by other covariates.
Obesity (2013) 21, E56-E63. doi:10.1002/oby.20047
Introduction
Hypothalamic-pituitary-adrenal (HPA) axis dysfunction is associated
with obesity and the metabolic syndrome (1). Greater adrenocortico-
tropin hormone responses to stimulatory testing have been observed
in subjects with higher waist-to-hip ratios (WHR) (2) or higher body
mass index (BMI) (3). Other studies have suggested that higher
WHR or abdominal sagittal diameter is associated with blunted
dexamethasone suppression of cortisol (4), higher cortisol awakening
response (CAR) (5), higher serum cortisol during stress (6), and
lower awakening cortisol levels (7-9). Higher BMI has been found
to be associated with lower morning cortisol (10); however, higher
urine-free cortisol (UFC) has been positively associated with WHR
(2,11), subcutaneous adipose tissue (12), BMI (13), visceral fat area
by magnetic resonance imaging (14), and the presence of metabolic
syndrome (15). Purnell et al. (16) found increased cortisol produc-
tion rate and free cortisol levels to be associated with higher intra-
abdominal fat via computed tomography (CT).
In contrast, other studies have reported conflicting results. Some anal-
yses of small studies have described no correlations between UFC and
visceral fat as measured by CT (17) and WHR (7,17,18). Other studies
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have shown no association between WHR and dexamethasone-sup-
pressed cortisol levels (7,11), and in one study, higher BMI actually
associated with lower dexamethasone-suppressed cortisol levels (13).
Studies of the association of the diurnal cortisol profile with
anthropometry measures of adiposity have shown mixed results.
Higher WHR has been associated with lower diurnal cortisol vari-
ability (19,20) and lower cortisol levels (21). Although CAR has
been positively associated with WHR (5) and WC (22), others found
an inverse association between awakening or morning cortisols and
BMI (23,24). Kumari et al. (24) noted from a large population-based
study that the most flat diurnal salivary cortisol slopes were
observed among individuals with the highest and lowest BMI and
WC, possibly explaining the mixed findings in other studies. With
the exception of two large studies (23,24), studies to date have been
limited by small sample size, single gender, and/or single race/eth-
nicity. The Multiethnic Study of Atherosclerosis (MESA) Stress
Study collected diurnal salivary cortisol profiles on a subset of
1,002 ethnically diverse adult men and women and offered a unique
opportunity to examine the association of the HPA axis profile with
BMI (as a marker of overall adiposity) and WC (as a marker of cen-
tral adiposity). MESA is unique from other studies in having
detailed salivary cortisol collection (8 time points per day over 3
days) to permit examination of multiple components of the diurnal
cortisol curve with body fat measures. We were also unique in being
able to exploit additional data collected from the main MESA study
to examine potential confounders/explanatory factors in these associ-
ations. Based on prior reported studies, we hypothesized that lower
diurnal cortisol variability, higher CAR, and higher cortisol area
under the curve (AUC) as a marker of cortisol production would be
associated with higher BMI and WC.
Methods
Study population
MESA is a multicenter longitudinal cohort study of the prevalence
and correlates of subclinical cardiovascular disease and the factors
that influence its progression (25). Individuals were not eligible to
participate in MESA if they had clinical cardiovascular disease at
baseline (25). Between July 2000 and August 2002, 6,814 men and
women who identified themselves as White, Black, Hispanic, or
Chinese and aged 45-84 years were enrolled from six different US
communities. Details on the sampling frames and the cohort exami-
nation procedures are published (25).
Between July 2004 and November 2006, in conjunction with the
second and third follow-up examinations of the full MESA sample,
a subsample of 1,002 White, Hispanic, and African-American partic-
ipants from either Los Angeles County, California or Northern Man-
hattan and the Bronx, New York participated in a substudy of bio-
logical stress markers (the MESA Stress Study), which included
repeat assessments of salivary cortisol (26). Enrollment continued
until 500 participants were enrolled at each site. Informed consent
was obtained from each participant, and the study was approved by
the Institutional Review Boards of each institution.
Hormonal measures
MESA Stress Study participants were instructed, by trained staff, to
collect six salivary cortisol samples a day (directly on awakening,
30 min after waking, 10:00 a.m., 12:00 p.m. or before lunch which-
ever was earlier, 6:00 p.m. or before dinner whichever was earlier,
and at bedtime). Salivary cortisol measure is free as opposed to
bound cortisol; thus, it is less prone to variability due to changes in
cortisol binding proteins (i.e., corticotrophin binding globulin and al-
bumin) and is the preferred method of measurement for dynamic
HPA axis studies (27). This daily collection protocol was repeated
on each of three successive week days; thus, each participant pro-
vided up to 18 cortisol measures. Participants recorded collection
time on special cards; in addition, a time-tracking device (Track
Caps) automatically registered the time at which cotton swabs were
extracted to collect each sample. The participants were informed of
this time-tracking device.
Saliva samples were collected using cotton swabs and stored at
20C until analysis. Before biochemical analysis, samples were
thawed and centrifuged at 3000 rpm for 3 min to obtain clear saliva
with low viscosity. Cortisol levels were determined using a commer-
cially available chemiluminescence assay with a high sensitivity of
0.16 ng/ml (IBL-Hamburg; Germany). Intra-assay and interassay
coefficients of variation are below 8%. For our analyses, all cortisol
measures at each time over 3 days were treated as repeated meas-
ures and not averaged. Awakening cortisol was defined as the sali-
vary cortisol obtained at time zero. CAR rise was the cortisol rise
from time zero to 30-min postawakening. Early decline in cortisol
(CAR decline) was defined as 30-min postawakening to 2-h posta-
wakening. Late decline in cortisol was from 2-h postawakening to
bedtime (26). A few unusually high salivary cortisol values were
noted that did not seem physiologically plausible, and 20 such val-
ues were excluded based on being inappropriately high when com-
pared with other values for that time of day within the same subject.
Assessment of BMI, waist circumference,
and obesity
Weight and height were measured using a balanced beam scale and
a vertical ruler, respectively, with participants wearing light clothing
and no shoes. Height was recorded to the nearest 0.5 cm and weight
to the nearest 0.5 lb. BMI was calculated as weight (kg) divided by
height squared (m2). BMI categories are as defined by the World
Health Organization (1995) as normal (<25 kg/m2), grade 1 over-
weight (25-30 kg/m2), grade 2 overweight (30-40 kg/m2), and grade
3 overweight (>40 kg/ m2) (28). Waist circumference (WC) was
measured at the minimum abdominal girth. All anthropometric
measures were taken in duplicate and averaged.
Covariates
Data on age, race/ethnicity, sex, years of education, cigarette smok-
ing, highest level of education achieved, and annual income by self-
report using standard protocols were previously described (25). The
analysis of socioeconomic status was simplified by the use of a sin-
gle wealth-income index variable described by Hajat et al. (29).
This wealth-income index is a composite socioeconomic status mea-
sure that incorporates annual income and information about assets.
Prescription and over-the-counter medications were determined by
transcription of medications brought into clinic during each exam
(25). Smoking was assessed by self-report and categorized according
to current, ever, and never smokers. Because Badrick et al. (30)
showed higher salivary cortisol levels in current smokers only and
no differences among ex-smokers and never-smokers, we accounted
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for smoking by current smoking or noncurrent smoking status. Dia-
betes status was defined according to the 2003 American Diabetes
Association criteria as fasting glucose  7.0 mmol/l (126 mg/dl) or
use of hypoglycemic medication (oral agents and/or insulin).
Impaired fasting glucose was defined as a fasting glucose of 5.5-6.9
mmol/l (100 to 125 mg/dl) (31).
Statistical analysis
Analysis overview. In each of our analyses, we determined the
association of cortisol curve parameters with BMI and WC. For the
purpose of our analyses, we have defined our exposure variable as
the cortisol measurements and our outcome variables as BMI and
WC. Cortisol distribution was log-transformed due to skewed distribu-
tions. BMI was maintained as a continuous variable in some analyses
and a categorical variable in others. Because only 49 participants met
criteria for the grade 3 overweight category, our analyses combined
the grade 2 and grade 3 overweight groups. Specific details of our
analyses are summarized below; however, in general, the regression
coefficients derived from our linear regression models represent the
change in BMI (kg/m2) or WC (cm) per one unit increase in the log
of the cortisol variable. In the case of categorical BMI, the regression
coefficients represent the mean difference in the log of the cortisol
variable in individuals in the overweight categories when compared
with normal weight individuals (reference category). Because of sig-
nificant differences seen in cortisol according to diabetes status in
prior MESA analyses (32), secondary analyses were performed
excluding individuals with diabetes or impaired fasting glucose.
In the base model for these analyses, adjustments were made for
age, race/ethnicity, gender, and diabetes status. To explore potential
confounding or explanatory factors in our associations, we per-
formed the following additional multivariable adjustments: wealth-
income index (socioeconomic status marker), current smoking status,
and medications that have the potential to affect cortisol, namely b-
blockers, steroids, and hormone replacement therapy (33). Adjust-
ments for wake up time were made.
Derivation of salivary cortisol curve variables. Cortisol secre-
tion has a well-documented circadian pattern typified by a rapid
early morning peak within 30 to 45 min after waking followed by a
decline throughout the remainder of the day (26). To capture all the
relevant inflections of the circadian rhythm, we modeled our data
using the approach proposed by Ranjit et al. (26). Daily cortisol val-
ues were modeled as a function of time since wake up, using linear
regression mixed model splines with ‘‘knots’’ located to capture the
ascending and descending phases of the CAR and the slower decline
over the course of the remainder of the day. Knots were located at
30 and 120 min after wake up based on prior MESA analyses (26).
The choice of the two knots was confirmed by the locally weighted
scatterplot smoothing (LOESS) curve on the diurnal cortisol level.
The presence of the knots allowed the relationship between time af-
ter wake up and cortisol levels (i.e., slope associated with time) to
vary over the day.
Similar to Ranjit et al., we obtained the following key parameters of
the spline models: the intercept (mean cortisol value at time 0 or at
wake time, called ‘‘awakening cortisol’’), the slope in cortisol from
wake time to 30-min postawakening (the rapidly changing ascending
CAR slope, called CAR), the slope in cortisol from 30 min to 120-
min postawakening (the rapidly descending CAR slope, called
‘‘early decline’’), and the slope in cortisol from 120-min postawak-
ening to bedtime, called ‘‘late decline’’ (26). This is depicted in an
exaggerated version of a diurnal cortisol curve in Figure 1. By
including covariates in the model as main effects and in interaction
with the different slope parameters, we were able to estimate how
these parameters varied as a function of BMI, after adjusting for
other risk factors and/or confounders (26).
We used mixed model linear regression to account for within-subject
correlation between repeated measures as well as a variable number of
repeated measures within a person and variations in the times of sample
collection, as done previously (26). To account for correlations, the
intercept and the time slope parameters for each person were treated as
random, and an unstructured covariance matrix was used to obtain ro-
bust standard errors. All covariates were treated as fixed effects.
We also calculated AUC summary measures to estimate the total
amount of cortisol exposure during the portions of the diurnal corti-
sol cycle outlined above. Based on the constructed spline model, we
calculated several adjusted AUC summary measures by BMI and
WC, including the full AUC (awakening to bedtime), CAR AUC
(awakening to 30 min), early decline AUC (30 min to 2 h), and late
decline AUC (2 h to bedtime) (Figure 1). For the purpose of this
analysis, bedtime is defined as 16-h postawakening (29).
In all of our analyses, a two-sided P-value of <0.05 was considered
statistically significant. All the analyses were carried out using SAS
version 9.2.
Results
Baseline characteristics
Baseline characteristics of the study participants are summarized in
Table 1 stratified by BMI category. Age and education were
FIGURE 1 Summary of diurnal cortisol curve parameters derived from mixed model
linear regression. Key: A ¼ awakening cortisol at time zero; B ¼ cortisol awakening
response (CAR) denoting rise from awakening to 30-min postawakening; C ¼ early
decline from 30-min postawakening to 2-h postawakening; D ¼ late decline from
2-h postawakening to bedtime; E ¼ area under the curve (AUC) for CAR; F ¼ AUC
for early decline; G ¼ AUC for late decline; the full AUC is the sum E þ F þ G.
Reprinted from Metabolism, 61, Champaneri S et al. Diurnal salivary cortisol and
urinary catecholamines are associated with diabetes mellitus: the Multi-Ethnic
Study of Atherosclerosis, pp. 986–995, Copyright (2012), with permission from
Elsevier (32).
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inversely associated with weight status, whereas African-American
or Hispanic race, female sex, WC, and prevalence of glucose disor-
ders were positively associated with weight status. Income, depres-
sive symptoms, and smoking status were not related to obesity.
There were some individuals taking medications that might con-
found the association between hormonal measures and BMI or WC
(33), including 10 on oral steroids, 27 on inhaled steroids, 71 on
hormone replacement therapy, and 346 on b-blockers. Among those
with normal BMI, there were only four individuals with BMI < 18
kg/m2.
Association of awakening cortisol, CAR, early
decline, late decline, and AUC with BMI and WC
Figure 2 depicts the variation in diurnal cortisol curve from awaken-
ing to bedtime based on BMI category with notably lower cortisol
values seen in those with higher BMI. This is more visibly apparent
in the awakening hours as depicted in Figure 3. Table 2 demon-
strates the individual cortisol variables relative to WC and BMI
modeled as continuous variables and adjusted for age, sex, race/eth-
nicity, and diabetes status. Both WC and BMI showed a significant
negative association with awakening cortisol, AUC awakening ris-
ing, and AUC early decline. No statistically significant differences
were noted in the awakening rise or late decline; however, the early
decline portion of the salivary curve was flattened with a signifi-
cantly positive association in the slope for both BMI and WC. Fol-
lowing additional adjustments for socioeconomic status, b-blockers,
steroid use, HRT use, and current smoking status, these associations
persisted, although some associations with total AUC were attenu-
ated. Findings were similar when BMI was modeled as a categorical
variable, although BMI category was not significantly associated
with the early decline and total AUC (data not shown). Because a
TABLE 1 Baseline characteristics of study population
Variable Category
BMI category
P-value
Normal
(n ¼ 233)
Grade 1
overweight
(n ¼ 413)
Grades 2 and
3 overweight
(n ¼ 355)
Age (mean 6 SD) 66.4 (10.4) 66.0 (10.0) 63.8 (8.9) 0.0014a
Adjusted income wealth index (mean 6 SD) 4.13 (2.29) 3.73 (2.33) 3.59 (2.27) 0.020a
Mean waist circumference (cm) (mean 6 SD) 85.4 (7.6) 96.9 (7.2) 111.3 (9.2) <0.0001b
Gender Male 48.5% 54.7% 38.3% <0.0001b
Female 51.5% 45.3% 61.7%
Race/ethnicity Caucasian 32.2% 17.9% 11.0% <0.0001b
African-American 25.8% 24.7% 34.9%
Hispanic 42.0% 57.4% 54.1%
Diabetes status Normal 78.1% 62.7% 49.0% <0.0001b
Impaired fasting glucose 14.6% 21.3% 24.8%
Diabetes 7.3% 16.0% 26.2%
Elevated depressive symptom status CES-D < 16 81.9% 82.1% 79.4% 0.595
CES-D < 16 18.1% 17.9% 20.6%
Education <High school 18.9% 30.8% 27.6% 0.013a
High school 20.2% 18.6% 22.0%
College 60.9% 50.6% 50.4%
Income ($) <16,000 21.4% 24.8% 25.6% 0.552
16,000–24,999 14.3% 15.6% 15.2%
25,000–34,999 15.6% 17.6% 18.7%
35,000–49,999 15.6% 15.6% 15.2%
50,000–74,999 13.8% 11.2% 13.8%
75,000 19.2% 15.1% 11.5%
b-Blocker use 32.3% 37.8% 34.5% 0.354
Smoking Current smoker 8.2% 11.7% 7.7% 0.131
Inhaled steroid use 2.2% 2.7% 3.2% 0.793
Oral steroid use 0.9% 0.7% 1.4% 0.622
Hormone replacement therapy since last visit (Female only) 9.9% 5.1% 7.6% 0.067
Note: BMI categories are defined as follows: normal (<25 kg/m2), grade 1 overweight (25–30 kg/m2), grade 2 overweight (30–40 kg/m2), and grade 3 overweight
(>40 kg/m2).
Abbreviation: CES-D, Center for Epidemiological Studies Depression Scale.
aP < 0.05.
bP < 0.0001.
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prior study suggested a nonlinear association between the diurnal
cortisol slope and BMI (29), we performed subsidiary analyses in
which a quadratic term was included for BMI and WC. The results
of these analyses were similar to those from the linear model, sug-
gesting that there was no nonlinear association between cortisol
and BMI and WC in our population.
Because cortisol profiles may vary by sex (34), we determined
whether there was effect modification by sex on the association
between cortisol curve parameters and BMI and WC. In stratified
analyses, the results suggested that the association between awak-
ening cortisol and AUC parameters and BMI was slightly stronger
in men than women (awakening cortisol: b ¼ 0.021, 95% CI:
0.031 to 0.011 in men and b ¼ 0.011, 95% CI: 0.019 to
0.002 in women; total AUC: b ¼ 0.16, 95% CI: 0.28 to
0.035 in men and b ¼ 0.044, 95% CI: 0.16 to 0.067 in
women). Sex-stratified associations were similar for WC (data not
shown). However, there was no evidence of statistical interaction,
and the direction of association was similar in men and women
(P-value ¼ 0.094 and 0.079 for sex interaction of cortisol curve
measures with BMI and WC, respectively). Measures of cortisol
FIGURE 2 Diurnal curve for entire sample set.
FIGURE 3 Diurnal curve during awakening hours.
TA
B
LE
2
M
e
a
n
d
if
fe
re
n
c
e
s
in
B
M
I
a
n
d
lo
g
W
C
fo
r
e
a
c
h
o
n
e
lo
g
-u
n
it
c
h
a
n
g
e
in
c
o
rt
is
o
l
p
a
ra
m
e
te
rs
fo
r
e
n
ti
re
c
o
h
o
rt
b
y
a
g
e
,
ra
c
e
/e
th
n
ic
it
y
,
g
e
n
d
e
r,
a
n
d
d
ia
b
e
te
s
s
ta
tu
s
b
-C
o
e
ff
ic
ie
n
t
(9
5
%
C
I)
B
M
Ia
W
a
is
t
c
ir
c
u
m
fe
re
n
c
e
a
B
M
Ib
W
a
is
t
c
ir
c
u
m
fe
re
n
c
e
b
Aw
ak
en
in
g
(ti
m
e
ze
ro
)
0
.0
15
2c
(
0.
02
17
to
0
.0
08
7)
0
.0
04
6c
(
0.
00
71
to
0
.0
02
1)
0
.0
14
1c
(
0.
02
05
to
0
.0
07
6)
0
.0
04
2c
(
0.
00
67
to
0
.0
01
8)
Aw
ak
en
in
g
ris
e
(a
w
ak
en
in
g
0
h
to
pe
ak
30
m
in
)
(s
lo
pe
)
0.
00
08
(
0.
01
13
to
0.
01
29
)
0
.0
00
3
(
0.
00
49
to
0.
00
43
)
0
.0
00
8
(
0.
01
31
to
0.
01
16
)
0
.0
00
9
(
0.
00
55
to
0.
00
38
)
Ea
rly
de
cl
in
e
(p
ea
k
30
m
in
to
2
h)
(s
lo
pe
)
0.
00
63
c
(0
.0
01
2–
0.
01
14
)
0.
00
22
c
(0
.0
00
1–
0.
00
42
)
0.
00
64
c
(0
.0
01
2–
0.
01
15
)
0.
00
23
c
(0
.0
00
2–
0.
00
43
)
La
te
de
cl
in
e
(2
h
to
be
dt
im
e
16
h)
(s
lo
pe
)
0.
00
01
(
0.
00
06
to
0.
00
08
)
0.
00
00
(
0.
00
03
to
0.
00
02
)
0.
00
01
(
0.
00
06
to
0.
00
08
)
0.
00
00
(
0.
00
03
to
0.
00
02
)
AU
C
fu
ll
ra
ng
e
(W
ak
in
g
0
h
to
be
dt
im
e
16
h)
(a
re
a)
0
.0
85
7c
(
0.
16
96
to
0
.0
01
8)
0
.0
28
4
(
0.
05
96
to
0.
00
28
)
0
.0
78
2
(
0.
16
24
to
0.
00
6)
0
.0
25
3
(
0.
05
65
to
0.
00
6)
AU
C
aw
ak
en
in
g
ris
in
g
(a
w
ak
en
in
g
0
h
to
pe
ak
30
m
in
)
(a
re
a)
0
.0
07
5c
(
0.
01
06
to
0
.0
04
4)
0
.0
02
3c
(
0.
00
35
to
0
.0
01
2)
0
.0
07
1c
(
0.
01
02
to
0
.0
04
1)
0
.0
02
2c
(
0.
00
34
to
0
.0
01
1)
AU
C
ea
rly
de
cl
in
e
(p
ea
k
30
m
in
to
2
h)
(a
re
a)
0
.0
15
1c
(
0.
02
33
to
0
.0
06
9)
0
.0
04
7c
(
0.
00
76
to
0
.0
01
7)
0
.0
14
5c
(
0.
02
27
to
0
.0
06
4)
0
.0
04
4c
(
0.
00
74
to
0
.0
01
5)
AU
C
la
te
de
cl
in
e
(2
h
to
be
dt
im
e
16
h)
(a
re
a)
0
.0
63
1
(
0.
13
99
to
0.
01
36
)
0
.0
21
4
(
0.
05
to
0.
00
72
)
0
.0
56
5
(
0.
13
36
to
0.
02
06
)
0
.0
18
6
(
0.
04
74
to
0.
01
01
)
N
O
T
E
:
b-
c
o
e
ff
ic
ie
n
ts
re
fle
c
t
re
la
tiv
e
in
c
re
a
se
in
sl
o
p
e
o
r
A
U
C
p
e
r
u
n
it
in
c
re
a
se
in
B
M
I
o
r
W
C
.
a
A
d
ju
st
e
d
va
lu
e
s
fo
r
a
g
e
,
ra
c
e
/e
th
n
ic
ity
,
se
x,
a
n
d
d
ia
b
e
te
s
st
a
tu
s.
b
A
d
d
iti
o
n
a
l
a
d
ju
st
m
e
n
ts
fo
r
so
c
io
e
c
o
n
o
m
ic
st
a
tu
s,
b
-b
lo
c
ke
rs
,
st
e
ro
id
s,
H
R
T
,
a
n
d
c
u
rr
e
n
t
sm
o
ki
n
g
.
c
P
<
0
.0
5
.
Obesity Neuroendocrine Hormones and Adiposity Champaneri et al.
www.obesityjournal.org Obesity | VOLUME 21 | NUMBER 1 | JANUARY 2013 E60
slope (awakening rise, early decline, and late decline) were not asso-
ciated with BMI or WC in either sex (data not shown).
Secondary analysis with exclusion of impaired
fasting glucose and diabetes subjects
The association between WC and BMI and cortisol variables among
individuals with normal fasting glucose is summarized in Table 3,
as the association of diabetes with WC and BMI and HPA measures
might confound the observed association. Following multivariable
adjustment, higher BMI and WC showed a significant inverse asso-
ciation with awakening cortisol, total AUC, AUC awakening rise,
AUC early decline, and AUC late decline. BMI and WC were not
associated with awakening rise, early decline, or late decline.
Discussion
In this study, we found a cross-sectional association of the diurnal
cortisol profile with markers of overall and abdominal obesity.
These findings were independent of demographics, socioeconomic
status, medications, and smoking. We noted a significant negative
association of BMI and WC with awakening cortisol and early
decline, as well as the respective AUC.
Studies to date analyzing cortisol levels in relation to obesity
markers have yielded mixed results. Our findings of an inverse asso-
ciation of BMI and WC with morning cortisol levels are consistent
with those of three other studies (8,20,35), all of which were fairly
large population-based samples; however, these studies were more
limited in age range and/or race/ethnicity. A few studies have noted
a positive correlation between urinary cortisols and WHR (2,11),
subcutaneous adipose tissue (12), and BMI (13). As suggested by
Walker et al. (8), this paradox may be due to enhanced peripheral
metabolic clearance of cortisol in obesity or altered central HPA
control. Bjorntorp et al. (20) have also noted that urinary collections
have their own inherent weaknesses, including lack of information
on the kinetics of HPA axis regulation.
The physiology of cortisol metabolism may explain these findings.
11-b-Hydroxysteroid dehydrogenase-1 (11b-HSD1) is an enzyme
that converts hormonally active glucocorticoids like cortisol into
inactive metabolites like cortisone; its expression is thought to cause
higher intra-adipose tissue cortisol levels in obese subjects, perhaps
through its reverse reductase action (1). Rask et al. (13) found that
higher BMI was associated with higher 11b-HSD1 by adipose tissue
biopsy, which would be difficult to detect in serum and salivary sam-
ples. They also suggest that perhaps the reductase activity is impaired
at the level of the liver, yielding lower serum levels. This may imply
that in obesity, there may be tissue-specific alterations in cortisol me-
tabolism (13). Travison et al. (9) found among 999 subjects followed
up over two separate visits that there was a negative correlation
between changes in serum cortisol levels collected within 4 h of wak-
ing and increases in BMI over time. They also suggest that perhaps
overexpression of 11b-HSD1 in adipose tissue may cause local regen-
eration of cortisol, but with minimal effect on circulating levels.
Long-term activation of HPA axis is associated with decreased diur-
nal variability of cortisol (36). It has been noted in men with
‘‘burned-out’’ diurnal cortisol secretion (including lower awakening
cortisol and flatter slope) that there is a negative correlation with
WHR (37). Total cortisol secretion was lower in this group with a
flatter diurnal cortisol curve when compared with men with a more
normal high-variability diurnal curve (37). Thus, low daily cortisol
variability may reflect a prior overstimulated HPA axis, and previ-
ously high cortisol levels may have stimulated visceral fat accumu-
lation (3). Because our study was cross-sectional, we cannot confirm
a temporal sequence.
Our study has several strengths. First, this is one of the largest popula-
tion-based studies to date reporting the association of awakening and
diurnal salivary cortisol with markers of overall and central obesity.
Second, salivary cortisol sample collection included the use of track
caps for recording sample times to increase compliance in sample col-
lection. Third, salivary cortisol sample collection occurred over 3
days, which has not been done in prior studies, allowing a more accu-
rate determination of each participant’s diurnal cortisol pattern.
Finally, we were able to adjust for smoking, many medications, and
other potentially confounding variables using data collected in MESA.
TABLE 3 Mean differences in BMI and log WC for each one log-unit change in cortisol parameters for individuals with normal
fasting glucose, adjusted for age, race/ethnicity, gender, socioeconomic status, b-blockers, steroids, HRT, and current
smoking
b-Coefficient (95% CI)
BMI Waist circumference
Awakening (time zero) 0.0205a (0.029 to 0.012) 0.0065a (0.0099 to 0.0032)
Awakening rise (awakening 0 h to peak 30 min) (slope) 0.0016 (0.016 to 0.019) 0.0001 (0.0065 to 0.0062)
Early decline (peak 30 min to 2 h) (slope) 0.0063 (0.001 to 0.013) 0.0026 (0.0002 to 0.0054)
Late decline (2 h to bedtime 16 h) (slope) 0.0002 (0.001 to 0.001) 0.0001 (0.0005 to 0.0002)
AUC full range (Waking 0 h to bedtime 16 h) (area) 0.1963a (0.297 to 0.096) 0.0627a (0.1007 to 0.0247)
AUC awakening rising (awakening 0 h to peak 30 min) (area) 0.0101a (0.014 to 0.006) 0.0033a (0.0049 to 0.0017)
AUC early decline (peak 30 min to 2 h) (area) 0.0225a (0.033 to 0.012) 0.0070a (0.011 to 0.0031)
AUC late decline (2 h to bedtime 16 h) (area) 0.1638a (0.256 to 0.072) 0.0524a (0.0869 to 0.0179)
Note: b-coefficients reflect relative increase in slope or AUC per unit increase in BMI or WC.
aP < 0.05.
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Several limitations should be kept in mind, however, in interpreting
our data. First, this is a cross-sectional study, and thus, we were
unable to determine whether hormonal dysfunction preceded or
occurred after developing higher levels of obesity. Second, many
medications can theoretically affect salivary cortisol (33), and our
study only had data on a subset of these. Third, we did not have
data to more objectively assess visceral fat content via abdominal
imaging. Associations of metabolic risk factors have been noted to
be less pronounced in peripheral obesity rather than central obesity
(37); however, we found similar patterns of association using our
estimate of overall obesity (BMI) and our estimate of central adipos-
ity (WC). Fourth, we did not have data on specific subgroups of
obese individuals who have been shown to have flattened diurnal
cortisol profiles, including those with atypical depression (38) and
sleep apnea (39); therefore, we could not examine these factors as
potential mediators and/or effect modifiers of our observed associa-
tions. Fifth, although we found significant associations between cor-
tisol curve parameters and BMI and WC, they were small and their
clinical significance uncertain; however, our associations are of sim-
ilar magnitude to that observed in other studies. For example, the
unadjusted correlation coefficient between waking cortisol and BMI
and WC were 0.15 (P < 0.0001) and 0.11 (P < 0.0001), respec-
tively, in our population. Other studies have found correlations of
0.09 to 0.26 between morning cortisol and BMI (12, 14, 24).
Finally, this study lacked data concerning sex steroid and growth
hormone levels, which may have been potential confounders in the
association as they may affect cortisol and body fat levels (20).
Our population-based study comprehensively examined components
of the diurnal cortisol curve in relation to obesity markers. The
long-term effect of dysregulation of the neuroendocrine stress sys-
tem (i.e., allostatic load) is thought to be one potential mechanism
through which individuals are predisposed to metabolic disorders
(40). Longitudinal studies to assess neuroendocrine tone over time
as adiposity develops are necessary to further delineate the role of
the HPA axis in the development of obesity.O
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